医学
药物警戒
疾病
重症监护医学
上市后监督
安全概况
药品
药理学
内科学
不利影响
标识
DOI:10.1080/14779072.2024.2354255
摘要
Background Recently FDA-approved drugs for cardiovascular disease (CVD) require robust post-marketing surveillance. The objective of this study was to assess their safety using a large pharmacovigilance database.
科研通智能强力驱动
Strongly Powered by AbleSci AI